Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1461	66108-95-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iohexol	An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. Molecular weight: 821.14 Formula: C19H26I3N3O9 CLOGP: -2.44 LIPINSKI: 3 HAC: 12 HDO: 8 TPSA: 199.89 ALOGS: -3.01 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iohexol

An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Molecular weight: 821.14
Formula: C19H26I3N3O9
CLOGP: -2.44
LIPINSKI: 3
HAC: 12
HDO: 8
TPSA: 199.89
ALOGS: -3.01
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	95 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4597.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.16 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.50 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.80 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAPK10,MAPK7,MAPK9,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70	35
kinase-selectivity-class	ALK,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CLK2,CLK4,DYRK1B,EIF2AK3,EPHB4,FLT3,FYN,GAK,GRK2,GSK3A,GSK3B,IRAK1,IRAK3,KDR,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK7,MARK4,PDK1,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK10,STK17A,STK33,SYK,TEK,TGFBR1,TTK,TYRO3,UHMK1,ULK1,ULK2	55
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Dec. 26, 1985	FDA	GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sneezing	961.14	29.90	276	9438	29593	90589140
Urticaria	863.30	29.90	488	9226	312246	90306487
Contrast media reaction	608.71	29.90	107	9607	1144	90617589
Pruritus	523.17	29.90	443	9271	541082	90077651
Contrast media allergy	506.67	29.90	106	9608	2975	90615758
Erythema	357.18	29.90	250	9464	228996	90389737
Throat irritation	356.67	29.90	149	9565	48546	90570187
Extravasation	281.40	29.90	65	9649	2899	90615834
Throat tightness	270.06	29.90	106	9608	29378	90589355
Dyspnoea	218.55	29.90	359	9355	880596	89738137
Anaphylactic reaction	175.66	29.90	112	9602	87412	90531321
Chest discomfort	167.73	29.90	130	9584	138235	90480498
Chills	147.01	29.90	118	9596	131863	90486870
Anaphylactic shock	136.54	29.90	67	9647	31550	90587183
Contrast encephalopathy	125.31	29.90	21	9693	164	90618569
Cough	101.12	29.90	158	9556	368804	90249929
Eye swelling	99.90	29.90	53	9661	29333	90589400
Eye pruritus	83.82	29.90	47	9667	28980	90589753
Rash maculo-papular	81.08	29.90	52	9662	40881	90577852
Laryngeal oedema	78.26	29.90	29	9685	6852	90611881
Drug ineffective	71.15	29.90	30	9684	1384268	89234465
Blood pressure decreased	68.85	29.90	60	9654	74835	90543898
Drug reaction with eosinophilia and systemic symptoms	64.76	29.90	46	9668	42712	90576021
Paraesthesia oral	64.63	29.90	41	9673	31618	90587115
Dysphagia	60.22	29.90	67	9647	112211	90506522
Pharyngeal oedema	58.88	29.90	29	9685	13742	90604991
Sensation of foreign body	58.62	29.90	23	9691	6343	90612390
Tachypnoea	57.46	29.90	33	9681	21276	90597457
Vomiting	55.78	29.90	198	9516	788095	89830638
Dysphonia	54.90	29.90	49	9665	63035	90555698
Cyanosis	52.11	29.90	30	9684	19425	90599308
Swelling face	51.47	29.90	53	9661	81299	90537434
Loss of consciousness	51.34	29.90	69	9645	140169	90478564
Hypotension	49.23	29.90	108	9606	325289	90293444
Pharyngeal swelling	48.74	29.90	23	9691	9921	90608812
Nasal pruritus	48.16	29.90	12	9702	738	90617995
Tremor	48.08	29.90	70	9644	153103	90465630
Anaphylactoid reaction	47.77	29.90	18	9696	4450	90614283
Fatigue	47.52	29.90	33	9681	1153990	89464743
Nasal congestion	46.83	29.90	51	9663	83363	90535370
Aneurysm ruptured	44.72	29.90	11	9703	641	90618092
Papule	43.86	29.90	20	9694	7982	90610751
Flushing	42.69	29.90	50	9664	88441	90530292
Eyelid oedema	42.60	29.90	22	9692	11512	90607221
Joint swelling	42.41	29.90	3	9711	503297	90115436
Off label use	42.16	29.90	34	9680	1102218	89516515
Lip swelling	41.79	29.90	34	9680	38576	90580157
Alopecia	41.58	29.90	3	9711	495068	90123665
Ocular hyperaemia	41.38	29.90	32	9682	33766	90584967
Patent ductus arteriosus	40.29	29.90	16	9698	4553	90614180
Rash	40.16	29.90	180	9534	795920	89822813
Swollen tongue	38.60	29.90	35	9679	45921	90572812
Meningitis chemical	36.36	29.90	8	9706	285	90618448
Bronchospasm	35.38	29.90	24	9690	20685	90598048
Arthralgia	35.09	29.90	20	9694	778502	89840231
Air embolism	34.43	29.90	8	9706	365	90618368
Meningitis aseptic	34.22	29.90	16	9698	6757	90611976
Lacrimation increased	33.95	29.90	26	9688	27036	90591697
Unresponsive to stimuli	33.93	29.90	30	9684	38091	90580642
Angioedema	33.54	29.90	38	9676	64838	90553895
Local anaesthetic systemic toxicity	33.47	29.90	13	9701	3487	90615246
Infusion site extravasation	33.32	29.90	18	9696	10310	90608423
Tongue pruritus	33.05	29.90	9	9705	784	90617949
Laryngeal discomfort	32.96	29.90	8	9706	441	90618292
Hypersensitivity	32.70	29.90	115	9599	454562	90164171
Nasopharyngitis	32.69	29.90	3	9711	407101	90211632
Foaming at mouth	32.51	29.90	10	9704	1340	90617393
Oropharyngeal discomfort	32.20	29.90	16	9698	7719	90611014
Acute kidney injury	30.25	29.90	89	9625	320298	90298435
Rash erythematous	30.09	29.90	36	9678	65068	90553665

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	681.24	27.51	304	6975	73732	42540324
Sneezing	636.55	27.51	159	7120	6204	42607852
Contrast media reaction	434.21	27.51	85	7194	1031	42613025
Contrast media allergy	412.55	27.51	77	7202	710	42613346
Pruritus	344.33	27.51	272	7007	188499	42425557
Erythema	270.01	27.51	189	7090	108604	42505452
Extravasation	181.39	27.51	48	7231	2342	42611714
Anaphylactic reaction	177.56	27.51	103	7176	42640	42571416
Rash maculo-papular	170.86	27.51	96	7183	37407	42576649
Chills	158.78	27.51	130	7149	93936	42520120
Contrast encephalopathy	144.17	27.51	25	7254	144	42613912
Anaphylactic shock	120.23	27.51	65	7214	23452	42590604
Throat tightness	112.51	27.51	47	7232	9552	42604504
Throat irritation	89.64	27.51	44	7235	12992	42601064
Dyspnoea	69.30	27.51	198	7081	442423	42171633
Drug reaction with eosinophilia and systemic symptoms	64.28	27.51	55	7224	42020	42572036
Acute kidney injury	62.00	27.51	169	7110	367168	42246888
Vomiting	61.01	27.51	145	7134	289578	42324478
Drug ineffective	49.63	27.51	23	7256	630174	41983882
Blood pressure decreased	49.07	27.51	55	7224	58277	42555779
Death	47.92	27.51	11	7268	471174	42142882
Chest discomfort	46.84	27.51	56	7223	63560	42550496
Off label use	46.23	27.51	26	7253	638309	41975747
Flushing	45.84	27.51	43	7236	36985	42577071
Anaphylactoid shock	43.05	27.51	11	7268	466	42613590
Eosinophilia	42.26	27.51	39	7240	32860	42581196
Rash	42.25	27.51	123	7156	276831	42337225
Eye pruritus	40.78	27.51	25	7254	11387	42602669
Hypersensitivity	39.60	27.51	55	7224	72315	42541741
Tachypnoea	38.65	27.51	31	7248	21631	42592425
Oxygen saturation decreased	36.64	27.51	50	7229	64637	42549419
Overlap syndrome	36.32	27.51	9	7270	336	42613720
Rash erythematous	35.44	27.51	35	7244	32056	42582000
Feeling hot	34.43	27.51	30	7249	23452	42590604
Nasal congestion	34.11	27.51	33	7246	29468	42584588
Rash maculovesicular	32.77	27.51	6	7273	49	42614007
Eyelid oedema	32.63	27.51	17	7262	5678	42608378
Eye swelling	32.43	27.51	22	7257	11898	42602158
Blister	32.26	27.51	31	7248	27459	42586597
Nephropathy toxic	31.97	27.51	25	7254	16813	42597243
Hypotension	31.47	27.51	106	7173	257525	42356531
Dysphoria	30.51	27.51	13	7266	2767	42611289
Pallor	29.13	27.51	30	7249	28856	42585200
Air embolism	28.77	27.51	7	7272	242	42613814
Swelling face	28.48	27.51	29	7250	27525	42586531
Nausea	28.25	27.51	138	7141	396661	42217395

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sneezing	1446.79	25.19	415	16137	31569	110541178
Urticaria	1229.85	25.19	696	15856	318161	110254586
Contrast media reaction	940.51	25.19	180	16372	2218	110570529
Contrast media allergy	829.81	25.19	172	16380	3251	110569496
Pruritus	780.38	25.19	663	15889	580897	109991850
Erythema	547.34	25.19	406	16146	291041	110281706
Extravasation	423.45	25.19	106	16446	4739	110568008
Throat irritation	395.26	25.19	182	16370	53370	110519377
Throat tightness	335.07	25.19	141	16411	33348	110539399
Anaphylactic reaction	314.83	25.19	202	16350	114098	110458649
Chills	294.65	25.19	237	16315	190343	110382404
Contrast encephalopathy	261.87	25.19	46	16506	336	110572411
Dyspnoea	259.65	25.19	533	16019	1106339	109466408
Rash maculo-papular	249.52	25.19	149	16403	74073	110498674
Anaphylactic shock	239.69	25.19	128	16424	51418	110521329
Chest discomfort	191	25.19	178	16374	173670	110399077
Eye swelling	128.59	25.19	73	16479	32975	110539772
Drug reaction with eosinophilia and systemic symptoms	124.29	25.19	101	16451	81994	110490753
Blood pressure decreased	113.30	25.19	111	16441	114980	110457767
Eye pruritus	113.18	25.19	67	16485	32708	110540039
Drug ineffective	109.04	25.19	46	16506	1520494	109052253
Cough	96.52	25.19	213	16339	461428	110111319
Off label use	94.47	25.19	54	16498	1500131	109072616
Acute kidney injury	92.39	25.19	255	16297	635175	109937572
Vomiting	92.17	25.19	322	16230	910353	109662394
Laryngeal oedema	90.42	25.19	39	16513	9768	110562979
Tachypnoea	89.87	25.19	62	16490	39333	110533414
Rash	84.50	25.19	292	16260	820672	109752075
Flushing	76.22	25.19	86	16466	104650	110468097
Hypotension	73.85	25.19	208	16344	523641	110049106
Pharyngeal swelling	70.68	25.19	35	16517	11997	110560750
Loss of consciousness	70.16	25.19	114	16438	196192	110376555
Dysphagia	68.71	25.19	99	16453	153501	110419246
Cyanosis	68.28	25.19	47	16505	29694	110543053
Swelling face	67.50	25.19	76	16476	92245	110480502
Pharyngeal oedema	65.81	25.19	37	16515	16391	110556356
Eyelid oedema	65.59	25.19	36	16516	15226	110557521
Nasal congestion	65.28	25.19	77	16475	98205	110474542
Rash erythematous	64.37	25.19	70	16482	81762	110490985
Dysphonia	63.33	25.19	67	16485	75862	110496885
Aneurysm ruptured	61.41	25.19	17	16535	1123	110571624
Papule	61.08	25.19	30	16522	10103	110562644
Air embolism	60.91	25.19	15	16537	625	110572122
Paraesthesia oral	60.81	25.19	46	16506	33625	110539122
Nephropathy toxic	59.75	25.19	42	16510	27436	110545311
Anaphylactoid shock	59.13	25.19	16	16536	970	110571777
Angioedema	58.63	25.19	73	16479	98427	110474320
Lip swelling	57.70	25.19	53	16499	50614	110522133
Lacrimation increased	57.49	25.19	43	16509	30907	110541840
Sensation of foreign body	55.32	25.19	26	16526	7949	110564798
Dysphoria	54.18	25.19	24	16528	6404	110566343
Eosinophilia	53.50	25.19	54	16498	57882	110514865
Hypersensitivity	52.60	25.19	156	16396	403842	110168905
Pallor	50.99	25.19	52	16500	56415	110516332
Anaphylactoid reaction	49.66	25.19	23	16529	6803	110565944
Blood pressure immeasurable	48.78	25.19	17	16535	2406	110570341
Death	48.51	25.19	22	16530	698847	109873900
Joint swelling	48.47	25.19	5	16547	442840	110129907
Meningitis chemical	47.27	25.19	11	16541	359	110572388
Ocular hyperaemia	44.54	25.19	41	16511	39245	110533502
Nausea	44.34	25.19	326	16226	1235364	109337383
Oxygen saturation decreased	44.09	25.19	82	16470	156900	110415847
Cold sweat	44.05	25.19	32	16520	21999	110550748
Infusion site extravasation	43.36	25.19	25	16527	11609	110561138
Condition aggravated	42.53	25.19	29	16523	734807	109837940
Cardiac arrest	42.37	25.19	92	16460	196661	110376086
Tongue pruritus	42.31	25.19	12	16540	866	110571881
Nasopharyngitis	41.77	25.19	5	16547	394356	110178391
Nasal pruritus	41.50	25.19	12	16540	928	110571819
Fatigue	40.86	25.19	75	16477	1215883	109356864
Hyperhidrosis	40.81	25.19	88	16464	187210	110385537
Weight decreased	40.70	25.19	10	16542	468047	110104700
Toxic skin eruption	39.82	25.19	33	16519	27482	110545265
Arthralgia	39.75	25.19	35	16517	779597	109793150
Tremor	39.55	25.19	91	16461	202141	110370606
Pneumonia	39.37	25.19	44	16508	876670	109696077
Fall	38.83	25.19	21	16531	603461	109969286
Product dose omission issue	36.90	25.19	3	16549	321779	110250968
Swollen tongue	36.33	25.19	45	16507	60317	110512430
Unresponsive to stimuli	35.92	25.19	46	16506	63744	110509003
Diarrhoea	35.90	25.19	73	16479	1139432	109433315
Shock	35.59	25.19	42	16510	53546	110519201
General physical health deterioration	35.23	25.19	10	16542	425285	110147462
Bronchospasm	35.14	25.19	32	16520	30207	110542540
Insomnia	34.86	25.19	6	16546	360584	110212163
Tachycardia	33.82	25.19	92	16460	226553	110346194
Toxicity to various agents	33.51	25.19	15	16537	480540	110092207
Pulse abnormal	33.40	25.19	15	16537	4134	110568613
Rash maculovesicular	33.24	25.19	6	16546	52	110572695
Product use in unapproved indication	32.74	25.19	13	16539	447364	110125383
Face oedema	32.37	25.19	32	16520	33437	110539310
Pain	31.94	25.19	59	16493	954896	109617851
Resuscitation	31.49	25.19	13	16539	2920	110569827
Rash pustular	31.17	25.19	21	16531	12808	110559939
Foaming at mouth	31.12	25.19	12	16540	2258	110570489
Sinusitis	30.83	25.19	4	16548	296684	110276063
Product use issue	30.54	25.19	5	16547	311690	110261057
Injection site extravasation	30.50	25.19	19	16533	10150	110562597
Respiratory distress	30.20	25.19	44	16508	68830	110503917
Decreased appetite	29.96	25.19	17	16535	475829	110096918
Feeling hot	29.95	25.19	51	16501	91055	110481692
Hepatic enzyme increased	29.60	25.19	6	16546	320886	110251861
Temperature intolerance	29.57	25.19	21	16531	13929	110558818
No adverse event	29.27	25.19	45	16507	73794	110498953
Hyperpyrexia	29.17	25.19	17	16535	8052	110564695
Pulse absent	28.67	25.19	19	16533	11273	110561474
Amaurosis	27.63	25.19	10	16542	1579	110571168
Enanthema	26.91	25.19	9	16543	1125	110571622
Meningitis aseptic	26.02	25.19	17	16535	9853	110562894
Laryngeal discomfort	25.91	25.19	8	16544	775	110571972
Renal tubular necrosis	25.59	25.19	27	16525	30448	110542299

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08AB02	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
FDA EPC	N0000180185	Radiographic Contrast Agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35703	xenobiotic
CHEBI has role	CHEBI:37338	radioopaque medium
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:78298	environmental contaminant
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media 11 drugs

iobitridol iodixanol iomeprol iopamidol iopentol iopromide iotrolan ioversol ioxaglic acid ioxilan metrizamide

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.73	acidic
pKa2	11.33	acidic
pKa3	12.2	acidic
pKa4	13.65	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
64.7%	IOHEXOL	AMNEAL	A217737	Nov. 13, 2025	RX	SOLUTION	INJECTION, ORAL, RECTAL	July 26, 2026	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

None

External reference:

ID	Source
4018251	VUID
N0000146581	NUI
D01817	KEGG_DRUG
4018251	VANDF
C0022005	UMLSCUI
CHEBI:31709	CHEBI
CHEMBL1200455	ChEMBL_ID
D007472	MESH_DESCRIPTOR_UI
DB01362	DRUGBANK_ID
4848	INN_ID
4419T9MX03	UNII
3730	PUBCHEM_CID
5956	RXNORM
195194	MMSL
4904	MMSL
d01456	MMSL
000673	NDDF
109218004	SNOMEDCT_US
395751002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1401	INJECTION, SOLUTION	140 mg	INTRAVENOUS	NDA	31 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1411	INJECTION, SOLUTION	180 mg	ORAL	NDA	31 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	31 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	31 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1413	INJECTION, SOLUTION	300 mg	INTRAVENOUS	NDA	31 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1414	INJECTION, SOLUTION	350 mg	INTRAVENOUS	NDA	31 sections
Omnipaque	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1414	INJECTION, SOLUTION	350 mg	INTRAVENOUS	NDA	31 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1415	SOLUTION	9 mg	ORAL	NDA	31 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1416	SOLUTION	12 mg	ORAL	NDA	31 sections
ORALTAG	HUMAN PRESCRIPTION DRUG LABEL	1	54702-501	FOR SOLUTION	4.50 g	ORAL	NDA	19 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	71872-7369	INJECTION, SOLUTION	240 mg	INTRAVASCULAR	NDA	31 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	71872-7370	INJECTION, SOLUTION	300 mg	RECTAL	NDA	31 sections
Iohexol	HUMAN PRESCRIPTION DRUG LABEL	1	80830-2466	INJECTION, SOLUTION	300 mg	INTRA-ARTICULAR	ANDA	26 sections
Iohexol	HUMAN PRESCRIPTION DRUG LABEL	1	80830-2467	INJECTION, SOLUTION	300 mg	INTRA-ARTICULAR	ANDA	26 sections
Iohexol	HUMAN PRESCRIPTION DRUG LABEL	1	80830-2468	INJECTION, SOLUTION	300 mg	INTRA-ARTICULAR	ANDA	26 sections
Iohexol	HUMAN PRESCRIPTION DRUG LABEL	1	80830-2471	INJECTION, SOLUTION	350 mg	INTRA-ARTICULAR	ANDA	26 sections
Iohexol	HUMAN PRESCRIPTION DRUG LABEL	1	80830-2472	INJECTION, SOLUTION	350 mg	INTRA-ARTICULAR	ANDA	26 sections
Iohexol	HUMAN PRESCRIPTION DRUG LABEL	1	80830-2473	INJECTION, SOLUTION	350 mg	INTRA-ARTICULAR	ANDA	26 sections

Ask DrugCentral

Try a sample question

iohexol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: